Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Gains from Sales and Divestitures (2019 - 2023)

Bicycle Therapeutics (BCYC) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $119144.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Sales and Divestitures rose 240.41% year-over-year to $119144.0, compared with a TTM value of $119144.0 through Dec 2023, up 240.41%, and an annual FY2023 reading of $119144.0, up 240.41% over the prior year.
  • Gains from Sales and Divestitures was $119144.0 for Q4 2023 at Bicycle Therapeutics, up from $99638.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $119144.0 in Q4 2023 and bottomed at $35000.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 3 years is $67853.8, with a median of $78781.0 recorded in 2023.
  • Peak annual rise in Gains from Sales and Divestitures hit 240.41% in 2023, while the deepest fall reached 62.82% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $83947.0 in 2019, then plummeted by 58.31% to $35000.0 in 2022, then soared by 240.41% to $119144.0 in 2023.
  • Business Quant data shows Gains from Sales and Divestitures for BCYC at $119144.0 in Q4 2023, $99638.0 in Q3 2023, and $78781.0 in Q2 2023.